AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23324310 — intervention group
Group type: COMPARATOR
Intervention: MDA measured in serum of patients with ARDS
Number of subjects: 0
Study 23324310 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial measurements of MDA in serum of patients
Number of subjects: 0
Study 21598186 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining themselves flossing while engaging the motor system (touching a piece of floss)
Number of subjects: 0
Study 21598186 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging the motor system during the video
Number of subjects: 0
Study 21598186 — intervention group
Group type: COMPARATOR
Intervention: Watching the video without engaging the motor system
Number of subjects: 0
Study 18576334 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly plus weekly methotrexate (MTX; > or =15 mg)
Number of subjects: 201
Study 18576334 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg once weekly plus weekly methotrexate (MTX; > or =15 mg) plus placebo
Number of subjects: 201
Study 18576334 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 201
Study 18576334 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg once weekly
Number of subjects: 201
Study 16490020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra), flexible-dose (25 mg, 50 mg, or 100 mg) for 10 weeks
Number of subjects: 93
Study 16490020 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SEAR scores in subjects with ED
Number of subjects: 93
Study 16490020 — intervention group
Group type: COMPARATOR
Intervention: Control group (men without ED, did not take sildenafil)
Number of subjects: 93
Study 14618035 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy (amiodarone, propafenone, flecainide, sotalol)
Number of subjects: 68
Study 14618035 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic drug therapy
Number of subjects: 68
Study 11111392 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine plus antibiotics
Number of subjects: 122
Study 11111392 — intervention group
Group type: EXPERIMENTAL
Intervention: bismuth plus antibiotics
Number of subjects: 122
Study 11111392 — intervention group
Group type: COMPARATOR
Intervention: ranitidine alone
Number of subjects: 122
Study 9179631 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (adjuvant selective serotonin reuptake inhibitor)
Number of subjects: 0
Study 8473405 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human GIP (1 pmol/kg.min)
Number of subjects: 8
Study 8473405 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human GLP-1 (0.3 pmol/kg.min)
Number of subjects: 8
Study 8473405 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of GIP and GLP-1
Number of subjects: 8
Study 8473405 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose of GLP-1 (0.15 pmol/kg.min)
Number of subjects: 8
Study 8473405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 4064911 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerance training on Pursuit Rotor task with reinforcement (group E)
Number of subjects: 20
Study 4064911 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerance training on Pursuit Rotor task with reinforcement (group R)
Number of subjects: 20
Study 4064911 — intervention group
Group type: COMPARATOR
Intervention: Pursuit Rotor task under alcohol without reinforcement (group P)
Number of subjects: 20
Study 4064911 — intervention group
Group type: COMPARATOR
Intervention: Pursuit Rotor task with reinforcement before alcohol (group A)
Number of subjects: 20
Study 4064911 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement for Tracometer performance (group E)
Number of subjects: 20
Study 4064911 — intervention group
Group type: COMPARATOR
Intervention: Reinforcement for Tracometer performance (group R)
Number of subjects: 20
Study 29966816 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization intervention (Connect to Protect, C2P®)
Number of subjects: 1225
Study 29966816 — intervention group
Group type: COMPARATOR
Intervention: Standard voluntary counseling and testing (VCT) control
Number of subjects: 1225
Study 25946576 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin (single IV dose)
Number of subjects: 180
Study 25946576 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (IV infusion)
Number of subjects: 180
Study 25437032 — intervention group
Group type: EXPERIMENTAL
Intervention: WLS Forte (FitForMe, Rotterdam, the Netherlands) - contains vitamin B12 14000% RDA, iron 500% RDA, folic acid 300% RDA
Number of subjects: 148
Study 25437032 — intervention group
Group type: COMPARATOR
Intervention: Standard multivitamin supplement (sMVS) - contains approximately 100% of the recommended daily allowance (RDA) for iron, vitamin B12, and folic acid
Number of subjects: 148
Study 23152133 — intervention group
Group type: EXPERIMENTAL
Intervention: OUTBACK(®) LTD Re‐Entry Catheter
Number of subjects: 52
Study 23152133 — intervention group
Group type: COMPARATOR
Intervention: Manual reentry technique
Number of subjects: 52
Study 19913611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate (0.1 mmol/kg/day)
Number of subjects: 9
Study 19913611 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 9
Study 18006892 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 435
Study 18006892 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 435
Study 18006892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 435
Study 16030050 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1000 mg bid for 1 year
Number of subjects: 32
Study 16030050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12850992 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject-performed task (SPT)
Number of subjects: 0
Study 12850992 — intervention group
Group type: COMPARATOR
Intervention: Verbal task (VT)
Number of subjects: 0
Study 12850992 — intervention group
Group type: EXPERIMENTAL
Intervention: Item-specific orienting task for VTs
Number of subjects: 0
Study 10543488 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 U/kg of heparin
Number of subjects: 24
Study 10543488 — intervention group
Group type: COMPARATOR
Intervention: 150 U/kg of heparin
Number of subjects: 24
Study 8983892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once daily
Number of subjects: 82
Study 8983892 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin 400 mg twice daily
Number of subjects: 82
Study 2029814 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanic thermometer
Number of subjects: 0
Study 2029814 — intervention group
Group type: COMPARATOR
Intervention: Oral and rectal thermometers
Number of subjects: 0
Study 35824 — intervention group
Group type: COMPARATOR
Intervention: salazosulphapyridine (SASP) 1 g X 3
Number of subjects: 33
Study 35824 — intervention group
Group type: EXPERIMENTAL
Intervention: methyl-salazosulphapyridine (methyl-SASP) 125 mg x 3
Number of subjects: 33
Study 31818831 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS intervention targeting adherence to cardiovascular medications
Number of subjects: 0
Study 28866264 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl solution 100ml/h for 3 days
Number of subjects: 120
Study 28866264 — intervention group
Group type: COMPARATOR
Intervention: No intravenous fluid
Number of subjects: 120
Study 25707929 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfilicon A
Number of subjects: 21
Study 25707929 — intervention group
Group type: COMPARATOR
Intervention: Lotrafilcon B
Number of subjects: 21
Study 23958184 — intervention group
Group type: EXPERIMENTAL
Intervention: SurvivorCare intervention (nurse-led supportive care program including educational materials, tailored care plan, face-to-face consultation, and three telephone calls)
Number of subjects: 0
Study 23958184 — intervention group
Group type: COMPARATOR
Intervention: Usual post-treatment care (control group)
Number of subjects: 0
Study 21377071 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lornoxicam 16 mg
Number of subjects: 40
Study 21377071 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 40
Study 19877047 — intervention group
Group type: EXPERIMENTAL
Intervention: dnaJP1 (25 mg daily for 6 months)
Number of subjects: 160
Study 19877047 — intervention group
Group type: EXPERIMENTAL
Intervention: dnaJP1
Number of subjects: 160
Study 19877047 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dnaJP1 and hydroxychloroquine (HCQ)
Number of subjects: 160
Study 19877047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 16966991 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind subxiphoid pericardiotomy (BSP)
Number of subjects: 83
Study 16966991 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous catheter drainage (PCD)
Number of subjects: 83
Study 16966991 — intervention group
Group type: COMPARATOR
Intervention: BSP and PCD (combined outcome)
Number of subjects: 83
Study 15577136 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX)
Number of subjects: 0
Study 15577136 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy
Number of subjects: 0
Study 11133891 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (1.5 h/day, endurance‐type exercise)
Number of subjects: 40
Study 11133891 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 11542396 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light
Number of subjects: 45
Study 11542396 — intervention group
Group type: EXPERIMENTAL
Intervention: LEET
Number of subjects: 45
Study 11542396 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 45
Study 8236004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5% ophthalmic solution, four times a day for seven days
Number of subjects: 93
Study 8236004 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 93
Study 2950709 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine treatment
Number of subjects: 20
Study 2950709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29566189 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation to both mother and child (MCI)
Number of subjects: 360
Study 29566189 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation to only the child (CI)
Number of subjects: 360
Study 29566189 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (C)
Number of subjects: 360
Study 26852899 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-PDT
Number of subjects: 22
Study 26852899 — intervention group
Group type: EXPERIMENTAL
Intervention: S-pulse-PDT
Number of subjects: 22
Study 26852899 — intervention group
Group type: COMPARATOR
Intervention: Conventional PDT
Number of subjects: 22
Study 24733880 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment and self‐defense intervention (six 2‐hour sessions)
Number of subjects: 1978
Study 24733880 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment and self‐defense intervention
Number of subjects: 1978
Study 24733880 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) group (life skills class, n = 428)
Number of subjects: 1978
Study 24733880 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) group
Number of subjects: 1978
Study 23434302 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated health management model
Number of subjects: 600
Study 23434302 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 600
Study 20201959 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 12
Study 20201959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross polarized light (CPL) method
Number of subjects: 12
Study 20201959 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence diagnosis (FD) method
Number of subjects: 12
Study 20201959 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 12
Study 17587217 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg once daily
Number of subjects: 798
Study 17587217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 798
Study 15662690 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuchal translucency measurement
Number of subjects: 0
Study 15662690 — intervention group
Group type: EXPERIMENTAL
Intervention: Second trimester maternal serum test
Number of subjects: 0
Study 15662690 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12869456 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic tape
Number of subjects: 87
Study 12869456 — intervention group
Group type: COMPARATOR
Intervention: Control tape
Number of subjects: 87
Study 12869456 — intervention group
Group type: COMPARATOR
Intervention: No tape
Number of subjects: 87
Study 10555898 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine supplementation (8 g daily for 28 days)
Number of subjects: 0
Study 10555898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10555898 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (iontophoresis)
Number of subjects: 0
Study 8873688 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (0.005 to 0.10 mg/kg)
Number of subjects: 58
Study 1994758 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation with midazolam (0.5 mg) and fentanyl (25 micrograms) administered via PCA infuser
Number of subjects: 40
Study 1994758 — intervention group
Group type: COMPARATOR
Intervention: Sedation administered by the anesthesiologist with 0.5‐1.0 mg intravenous midazolam and 25‐50 micrograms intravenous fentanyl
Number of subjects: 40
Study 6659643 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (Di) 2.0 mg/kg intravenous
Number of subjects: 7
Study 6659643 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (Me) 3.0 mg/kg intravenous
Number of subjects: 7
Study 6659643 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenon (Pr) 1.5 mg/kg intravenous
Number of subjects: 7
Study 6659643 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (Di) 4 X 200 mg/day oral
Number of subjects: 7
Study 6659643 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (Me) 4 X 200 mg/day oral
Number of subjects: 7
Study 6659643 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenon (Pr) 3 X 300 mg/day oral
Number of subjects: 7
Study 31834000 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir + lamivudine
Number of subjects: 1433
Study 31834000 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir + tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 1433
Study 31014344 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (12-week course)
Number of subjects: 0
Study 31014344 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered steroids (used as rescue medication)
Number of subjects: 0
Study 31014344 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial design (three-arm trial)
Number of subjects: 0
Study 28672316 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 501
Study 28672316 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 501
Study 25425502 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5mg once daily
Number of subjects: 1519
Study 25425502 — intervention group
Group type: COMPARATOR
Intervention: glimepiride 1-4mg once daily
Number of subjects: 1519
Study 24012465 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings for 48 hours (Group A)
Number of subjects: 109
Study 24012465 — intervention group
Group type: COMPARATOR
Intervention: Compression stockings for 7 days (Group B)
Number of subjects: 109
Study 24012465 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasound imaging
Number of subjects: 109
Study 21132441 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval training (HIT)
Number of subjects: 20
Study 21132441 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HIT)
Number of subjects: 20
Study 20156769 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (960 mg thrice weekly for 18 months)
Number of subjects: 31
Study 20156769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 20156769 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 31
Study 16537811 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in CCG 2891
Number of subjects: 1641
Study 16537811 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in CCG 2961
Number of subjects: 1641
Study 16537811 — intervention group
Group type: COMPARATOR
Intervention: CCG 2961
Number of subjects: 1641
Study 14728579 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial Bank system
Number of subjects: 0
Study 14728579 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 9870976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive expectation cues
Number of subjects: 0
Study 9870976 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine conditioning with expectation cues
Number of subjects: 0
Study 9870976 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine conditioning alone
Number of subjects: 0
Study 9870976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac conditioning with expectation cues
Number of subjects: 0
Study 9870976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac conditioning alone
Number of subjects: 0
Study 8876546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS), 200 micrograms once daily
Number of subjects: 349
Study 8876546 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aqueous nasal spray (BDP), 168 micrograms twice daily
Number of subjects: 349
Study 8876546 — intervention group
Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 349
Study 1832527 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin alone for 6 weeks, then placebo plus rifampin, isoniazid, ethambutol, and clofazimine for 6 weeks
Number of subjects: 15
Study 1832527 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone, then clarithromycin plus rifampin, isoniazid, ethambutol, and clofazimine
Number of subjects: 15
Study 1832527 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus rifampin, isoniazid, ethambutol, and clofazimine
Number of subjects: 15
Study 6648357 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol, administered twice daily over a period of 1 week
Number of subjects: 0
Study 6648357 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, administered for 1 week
Number of subjects: 0
Study 6648357 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication for 1 week
Number of subjects: 0
Study 31040253 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant zoledronic acid (4 mg) intravenously at 1, 2, 3, 6, 9, and 12 months after surgery
Number of subjects: 14
Study 31040253 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 14
Study 29889851 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 267
Study 29889851 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 267
Study 27488378 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin-impregnated bone cement (1 g/40 g)
Number of subjects: 15
Study 27488378 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tobramycin (control group)
Number of subjects: 15
Study 24126931 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanicemine (AZD6765)
Number of subjects: 0
Study 24126931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22036088 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 75 mg/m² and cisplatin 100 mg/m² (6 cycles)
Number of subjects: 533
Study 22036088 — intervention group
Group type: EXPERIMENTAL
Intervention: Grades 3-4 oral mucositis
Number of subjects: 533
Study 22036088 — intervention group
Group type: EXPERIMENTAL
Intervention: Grades 1-2 nausea/vomiting
Number of subjects: 533
Study 22036088 — intervention group
Group type: EXPERIMENTAL
Intervention: Grades 1-2 thrombocytopenia
Number of subjects: 533
Study 22036088 — intervention group
Group type: EXPERIMENTAL
Intervention: Good histological response
Number of subjects: 533
Study 22036088 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal tumour site
Number of subjects: 533
Study 22036088 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 533
Study 22036088 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroblastic tumour
Number of subjects: 533
Study 18982233 — intervention group
Group type: EXPERIMENTAL
Intervention: Family psychoeducational intervention program
Number of subjects: 45
Study 18982233 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (control group)
Number of subjects: 45
Study 17092664 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy for 3 months followed by 3 months of continuous estrogen and progesterone combined therapy
Number of subjects: 38
Study 17092664 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous estrogen and progesterone therapy for 3 months
Number of subjects: 38
Study 17092664 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 38
Study 17092664 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (estrogen and progesterone)
Number of subjects: 38
Study 16187913 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH levels below 0.3 mU/L
Number of subjects: 96
Study 16187913 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal TSH levels (0.3-3.0 mU/L)
Number of subjects: 96
Study 16187913 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH levels above 3 mU/L
Number of subjects: 96
Study 16187913 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH after ATDT cessation
Number of subjects: 96